Evaxion Biotech is a clinical-stage biotech company that leverages artificial intelligence in the development of immunotherapy treatments for cancers, bacterial diseases, and viral infections, including several vaccine candidates in the pre-clinical phase. The company has multiple programs underway, including EVX-01 and EVX-02, both of which are DNA-based cancer immunotherapies that are in clinical trials. Evaxion Biotech was founded in 2008 and is located in Denmark.